Solution Biologics Sdn Bhd

	Lim Yong Hew, a Malaysian aged 60, is our founder and Group Managing Director of the Solution Group Berhad. He graduated with a Bachelor of Engineering in Electrical Engineering (Hons) majoring in Control and Instrumentation from Salford University in 1982. He started his career with George Kent Malaysia as a Project Engineer. He then joined Foxboro Malaysia in 1985 as a Sales Engineer. He left the company to establish Solution Engineering Sdn Bhd (SESB) in 1988 where he took on the position of Managing Director. With his extensive business experience, Mr Lim has been the main driving force of the Group. His responsibilities cover various aspects of the Group's overall business development, direction and corporate strategy.

	Dato' Dr. Mohd Nazlee Kamal, PhD., a Malaysian aged 57, is our Director and Chief Executive Officer. He holds a PhD. in Chemical Engineering from University of Queensland, Brisbane, Australia, a M.App.Sc in Biotechnology from University of New South Wales. Australia, and a Bachelor of Science in Chemical Engineering from Oregon State University, Oregon, USA. Dato' Dr. Mohd Nazlee has over 30 years of diverse industry background in strategy, biotechnology and life sciences which including 15 years of executive management experience. He possesses strong expertise in both technical and business aspects in these areas. With the recognition of his wide industrial leadership, he played a pivotal role in the formulation of Malaysia's National Biotechnology Policy in 2005. Using his exceptional expertise and network, he provided consultation to various organisations and small medium enterprises within the industry. Dato' Dr. Mohd Nazlee served as a CEO of Bioeconomy Corporation (previously known as BiotechCorp) from 2011-2016. He played a leadership role in the rebranding and repositioning of the company to facilitate the nation's trajectory into the World Bio-economy arena. He was also invited to serve on the Global Bio-economy Council in Berlin from 2015-2017. Dato' Dr. Mohd Nazlee has a wealth of experience encompassing marketing and technical portfolio with multinational companies such as Amersham Biosciences, Sartorius and B. Braun Biotech. In addition, he invented the "External Spinfilter" now marketed by Sartorius BBI Systems (Patent No. PI9701436MY-131798-A). He has assumed leadership roles and also served on the boards of MAGIC, FRIM, NIBM, Bioeconomy Corporation (previously known as Biotech Corporation).

	Jay Padasian, a Malaysian aged 47, is our director and pharmacist. He holds a Bachelor of Pharmacy (Honours) from University of Wales Cardiff (Now Cardiff University); was registered with the Royal Pharmaceutical Society of Great Britain (MRPharmS) as well as registered with the Malaysian Pharmacy Board (RPh). He has over 25 years' experience within the Healthcare and Bio-related Industries. He has helmed senior leadership roles within local and regional subsidiaries of established MNCs such as B.Braun and Covidien (now Medtronics).He went on to help Malaysia's efforts to build the Healthcare Bio Industry as Senior Vice President, Healthcare at Malaysian Bioeconomy Corporation. He consults internationally in both the Government and Private Sectors on a broad-based area including Healthcare Bio Industry; Vaccines; Medical Technology; Industry Hub Development & Site Selection. He is also an entrepreneur and promoter of several start-up and trading companies. He has sat on various Technical Advisory Committees providing Subject Matter Expertise to various Malaysian Government Ministries and Agencies. He is part of the Technical & Commercial Evaluation Expert Panel for Research, Development & Commercialisation (R, D & C) under the Ministry of Science, Technology and Innovation (MOSTI). He has also contributed as a Member of the Board of Studies for two leading Malaysian Research Universities, Universiti Malaya and Universiti Sains Malaysia. He was a Steering Committee Member for National Key Economic Area (NKEA) Healthcare under Malaysia's Economic Transformation Program (ETP) and was a Cleared Government Advisor for the Trans-Pacific Partnership Agreement (TPPA). On the onset of Covid-19 pandemic, Jay was appointed a member of the National Experts Group Technology Development (EGTD) for Vaccines.

	Muhammad Lukmani Ibrahim, a Malaysian aged 61, is our director. He holds a Bachelor of Pharmacy (Honours) and a Registered Pharmacy Rph 1046; with the Pharmacy Board of Malaysia since 31 July 1985. Presently; a Fellow Consultant at the Centre for Regulatory Compliance, Universiti Kuala Lumpur, Royal College of Medicine Perak. National Services; as Subject Matter Expert WG 1/3-2; for MS 2424:2019 Halal Pharmaceuticals – General Requirement which is also as National Mirror Committee ((NMC) to technical committee Standards and Metrology Institute for Islamic Countries (SMIIC) and Convenor for TC16 - Halal Pharmaceutical Issues/WG 1; SMIIC; nominated by Malaysia Standard Department, Ministry of International Trade and Industry, He has over three decades of experience in various disciplines of Pharmaceutical Services. He began his career in 1985, as a Pharmacy Officer in the Pharmaceutical Service's Headquarter in Human Resource Department (now known as Human Capital Development). He then moved to Selangor State Enforcement as a Pharmacy Enforcement Officer in 1991, a responsibility that exposed him to the Enforcement Framework for the country in general and for the Selangor State in specific. In 1993, he enrolled in the National Pharmaceutical Regulatory Agency (NPRA), formerly known as the National Pharmaceutical Control Bureau (NPCB). He dedicated more than half of his career in NPRA, serving Compliance & Licensing Centre for 17 years. He started off as an auditor for Good Manufacturing and Distribution Practice (GMP/GSP), moving up to the top management level; appointed as the leader for the centre for two years before being promoted to Deputy Director of Enforcement in 2010 at the Service's Head Office and was appointed by the Minister of Health as the Secretary of the Malaysian Advertisement Board, Ministry of Health from 2011 to 2015. His other notable deliverable during his tenure as Deputy Director of Enforcement was the establishment of Pharmacy Enforcement Audit Activities (ADAP) for all 14 states throughout Malaysia, where he served as Chairman and developed the capacity and capability of the audit team. He was also a Chairman of the Pharmaceutical Enforcement Innovation and Creativity Committee from 2014 to 2016 that was responsible in revolutionising the culture of innovation within the nation's Enforcement's workforce. In 2015; he was reassigned to NPRA to lead The Centre Compliance & Licensing Centre as it's Deputy Director. In this field, he has spent up in total of 21 years of his 34 employment years, he has had responsibility not constrained to Malaysia but reached out to the international front through his work in ASEAN Regulatory Harmonization across various product categories. Acknowledged as a resource person and consultant at the international level; particularly in the GMP arena, he facilitated and consulted the ASEAN Consultative Committee for Standard and Quality Pharmaceutical Product Working Group (ACCSQ PPWG) since 2002. He was amongst the Panel of Expert (POE) for the Joint Sectoral Committee GMP Mutual Recognition Arrangements (MRAs) for ASEAN member states to accede as a Listed Inspection Services. Senior GMP expert/ Team Leader in developing Cosmetic GMP training modules in ASEAN Regulatory Harmonization; Chair of the ASEAN GMP Task Force for the GMP Guideline on Traditional Medicine and Health Supplement (TMHS), between 2015 until 2019, he was the Chairman cum Resource person for the development of 15 GMP Training Modules for Traditional Medicines and Health Supplement in ASEAN Regulatory Harmonization. He diligently delivered his role as the Consultant/Trainer on Good Manufacturing Practices (GMP) for the World Health Organisation (WHO) in the Assessment of the Implementation of cGMP Guidelines for Drug inspectors of the Bureau of Food and Drugs (BFAD) of the Philippines in the year 2002 and in 2003 to His Majesty's Government of Nepal Ministry Of Health Department Drug Administration. Beyond ASEAN, he represented Malaysia at the Pharmaceutical Inspection Co-operation Scheme (PIC/s) of which NPRA was acceded as the 26th Participating Authority from 1st January 2002; within the PIC/s circle he has served as Co-Rapporteur for the PIC/s Assessment of BFAD in 2013 and Saudi Arabia Food & Drug Authority in 2017 to become PIC/s Participating Authority. A subject matter expert for Halal Framework for Pharmaceuticals in the country since 2009. His contribution is enormous whilst the prime mover of the Malaysian standard of Halal Pharmaceutical guideline. He was an active member of the technical committee for MS 2424:2012 Halal Pharmaceutical Standards - General Guidelines where he instrumented and contributed continuously for Malaysia to be the lead country in the world to drive the Halal Pharmaceutical Standard. He endlessly provides technical guidance to the advancement of MS Halal Pharmaceutical-General Requirements MS 2425:2010 (cosmetics), and the revised MS Halal Pharmaceuticals-General Requirements MS 2424:2019. Both guidelines have served as a pivotal guide for industry players involved in the manufacturing of halal pharmaceutical products and notified cosmetics. In October 2019, he was appointed as permanent member of Steering Committee for Malaysian Halal Certification by Datuk Seri Dr. Mujahid bin Yusof, Minister in the Prime Minister's Department for Religious Affairs.

	Charles Lim Meng Yit, a Malaysian aged 67, is our Director. He graduated from University of Science Malaysia as a Pharmacist with a degree of B. Pharm with Honours. Charles Lim has a career, spanning more than 40 years, in the healthcare, life sciences, biotechnology and biopharmaceutical industry with long experience in sales, marketing & business development in Asia Pacificand techincal expertise in bioseparations from lab to production scale, cGMP bioproduction, downstream bioprocessing & development of biologics and vaccines, turnkey plasma fractionation projectsand GMP facility design. He is a frequent speaker and moderatorat local and International Seminars and Conferences on Biologics in the region and conducted protein and vaccine purification courses at institutes and universities. He began his career with the Ministry of Health, Malaysia, and after more than a decade as pharmacist and a technical expert in the life science industry in Malaysia he joined Pharmacia Biotech in 1992 to manage their business in South East Asia and became their Vice President, for their separations and downstream processing business in Asia Pacific after the acquisitions by Amersham and GE Healthcare, until 2007. He was also responsible for the cooperation with Pharmadule, Sweden the leading modular turkey facility construction company. Charles moved to Shanghai China in 2007 where he provided consulting services for business & distributor management, sourcing of funds, technology transfer & acquisition in China and Asia Pacificfor CLIENTS International HK, Atoll GmbH, BIA Separations Austria and Bio-Works Co. Ltd UK. He also teamed up with Emergene GmbH (CEO Dr Joachim Walter) to provide business plan and consultations for turnkey MAB production. He was also expert advisor to Thailand Center of Excellence for Life Sciences (TCELS). Charles Lim served as a GM of BIA Separations Co. Ltd. China & Asia Pacific, an Austrian based company, from 2010 - 2014 and championed monolith chromatograhy technology for downstream processing of large biomolecules such a viruses and plasmids. Currently based in Suzhou, Charles Lim is Consultant and Deputy General Manager, International Business of Lisure Science (Suzhou) Co., Ltd the leading Downstream Processing Systems and Solution Provider for the biopharmaceutical industry in China and he has also consulted for other companies such as Charles River Laboratories USA, VirusSure Austria, Suzhou Nanomicro Technology Company, Morimatsu (China) Group and some chinese biologics manufacturers. Charles has a vast network and and knowledge of the biopharmaceutical industry in China.

Lim Yong Hew, a Malaysian aged 60, is our founder and Group Managing Director of the Solution Group Berhad. He graduated with a Bachelor of Engineering in Electrical Engineering (Hons) majoring in Control and Instrumentation from Salford University in 1982. He started his career with George Kent Malaysia as a Project Engineer. He then joined Foxboro Malaysia in 1985 as a Sales Engineer. He left the company to establish Solution Engineering Sdn Bhd (SESB) in 1988 where he took on the position of Managing Director. With his extensive business experience, Mr Lim has been the main driving force of the Group. His responsibilities cover various aspects of the Group's overall business development, direction and corporate strategy.

Dato' Dr. Mohd Nazlee Kamal, PhD., a Malaysian aged 57, is our Director and Chief Executive Officer. He holds a PhD. in Chemical Engineering from University of Queensland, Brisbane, Australia, a M.App.Sc in Biotechnology from University of New South Wales. Australia, and a Bachelor of Science in Chemical Engineering from Oregon State University, Oregon, USA.

Dato' Dr. Mohd Nazlee has over 30 years of diverse industry background in strategy, biotechnology and life sciences which including 15 years of executive management experience. He possesses strong expertise in both technical and business aspects in these areas. With the recognition of his wide industrial leadership, he played a pivotal role in the formulation of Malaysia's National Biotechnology Policy in 2005. Using his exceptional expertise and network, he provided consultation to various organisations and small medium enterprises within the industry.

Dato' Dr. Mohd Nazlee served as a CEO of Bioeconomy Corporation (previously known as BiotechCorp) from 2011-2016. He played a leadership role in the rebranding and repositioning of the company to facilitate the nation's trajectory into the World Bio-economy arena. He was also invited to serve on the Global Bio-economy Council in Berlin from 2015-2017.

Dato' Dr. Mohd Nazlee has a wealth of experience encompassing marketing and technical portfolio with multinational companies such as Amersham Biosciences, Sartorius and B. Braun Biotech. In addition, he invented the "External Spinfilter" now marketed by Sartorius BBI Systems (Patent No. PI9701436MY-131798-A).

He has assumed leadership roles and also served on the boards of MAGIC, FRIM, NIBM, Bioeconomy Corporation (previously known as Biotech Corporation).

Jay Padasian, a Malaysian aged 47, is our director and pharmacist. He holds a Bachelor of Pharmacy (Honours) from University of Wales Cardiff (Now Cardiff University); was registered with the Royal Pharmaceutical Society of Great Britain (MRPharmS) as well as registered with the Malaysian Pharmacy Board (RPh).

He has over 25 years' experience within the Healthcare and Bio-related Industries. He has helmed senior leadership roles within local and regional subsidiaries of established MNCs such as B.Braun and Covidien (now Medtronics).He went on to help Malaysia's efforts to build the Healthcare Bio Industry as Senior Vice President, Healthcare at Malaysian Bioeconomy Corporation.

He consults internationally in both the Government and Private Sectors on a broad-based area including Healthcare Bio Industry; Vaccines; Medical Technology; Industry Hub Development & Site Selection. He is also an entrepreneur and promoter of several start-up and trading companies.

He has sat on various Technical Advisory Committees providing Subject Matter Expertise to various Malaysian Government Ministries and Agencies. He is part of the Technical & Commercial Evaluation Expert Panel for Research, Development & Commercialisation (R, D & C) under the Ministry of Science, Technology and Innovation (MOSTI). He has also contributed as a Member of the Board of Studies for two leading Malaysian Research Universities, Universiti Malaya and Universiti Sains Malaysia.

He was a Steering Committee Member for National Key Economic Area (NKEA) Healthcare under Malaysia's Economic Transformation Program (ETP) and was a Cleared Government Advisor for the Trans-Pacific Partnership Agreement (TPPA). On the onset of Covid-19 pandemic, Jay was appointed a member of the National Experts Group Technology Development (EGTD) for Vaccines.

Muhammad Lukmani Ibrahim, a Malaysian aged 61, is our director. He holds a Bachelor of Pharmacy (Honours) and a Registered Pharmacy Rph 1046; with the Pharmacy Board of Malaysia since 31 July 1985. Presently; a Fellow Consultant at the Centre for Regulatory Compliance, Universiti Kuala Lumpur, Royal College of Medicine Perak. National Services; as Subject Matter Expert WG 1/3-2; for MS 2424:2019 Halal Pharmaceuticals – General Requirement which is also as National Mirror Committee ((NMC) to technical committee Standards and Metrology Institute for Islamic Countries (SMIIC) and Convenor for TC16 - Halal Pharmaceutical Issues/WG 1; SMIIC; nominated by Malaysia Standard Department, Ministry of International Trade and Industry.

He has over three decades of experience in various disciplines of Pharmaceutical Services. He began his career in 1985, as a Pharmacy Officer in the Pharmaceutical Service's Headquarter in Human Resource Department (now known as Human Capital Development). He then moved to Selangor State Enforcement as a Pharmacy Enforcement Officer in 1991, a responsibility that exposed him to the Enforcement Framework for the country in general and for the Selangor State in specific.

In 1993, he enrolled in the National Pharmaceutical Regulatory Agency (NPRA), formerly known as the National Pharmaceutical Control Bureau (NPCB). He dedicated more than half of his career in NPRA, serving Compliance & Licensing Centre for 17 years. He started off as an auditor for Good Manufacturing and Distribution Practice (GMP/GSP), moving up to the top management level; appointed as the leader for the centre for two years before being promoted to Deputy Director of Enforcement in 2010 at the Service's Head Office and was appointed by the Minister of Health as the Secretary of the Malaysian Advertisement Board, Ministry of Health from 2011 to 2015. His other notable deliverable during his tenure as Deputy Director of Enforcement was the establishment of Pharmacy Enforcement Audit Activities (ADAP) for all 14 states throughout Malaysia, where he served as Chairman and developed the capacity and capability of the audit team. He was also a Chairman of the Pharmaceutical Enforcement Innovation and Creativity Committee from 2014 to 2016 that was responsible in revolutionising the culture of innovation within the nation's Enforcement's workforce.

In 2015; he was reassigned to NPRA to lead The Centre Compliance & Licensing Centre as it's Deputy Director. In this field, he has spent up in total of 21 years of his 34 employment years, he has had responsibility not constrained to Malaysia but reached out to the international front through his work in ASEAN Regulatory Harmonization across various product categories. Acknowledged as a resource person and consultant at the international level; particularly in the GMP arena, he facilitated and consulted the ASEAN Consultative Committee for Standard and Quality Pharmaceutical Product Working Group (ACCSQ PPWG) since 2002. He was amongst the Panel of Expert (POE) for the Joint Sectoral Committee GMP Mutual Recognition Arrangements (MRAs) for ASEAN member states to accede as a Listed Inspection Services. Senior GMP expert/ Team Leader in developing Cosmetic GMP training modules in ASEAN Regulatory Harmonization; Chair of the ASEAN GMP Task Force for the GMP Guideline on Traditional Medicine and Health Supplement (TMHS), between 2015 until 2019, he was the Chairman cum Resource person for the development of 15 GMP Training Modules for Traditional Medicines and Health Supplement in ASEAN Regulatory Harmonization. He diligently delivered his role as the Consultant/Trainer on Good Manufacturing Practices (GMP) for the World Health Organisation (WHO) in the Assessment of the Implementation of cGMP Guidelines for Drug inspectors of the Bureau of Food and Drugs (BFAD) of the Philippines in the year 2002 and in 2003 to His Majesty's Government of Nepal Ministry Of Health Department Drug Administration.

Beyond ASEAN, he represented Malaysia at the Pharmaceutical Inspection Co-operation Scheme (PIC/s) of which NPRA was acceded as the 26th Participating Authority from 1st January 2002; within the PIC/s circle he has served as Co-Rapporteur for the PIC/s Assessment of BFAD in 2013 and Saudi Arabia Food & Drug Authority in 2017 to become PIC/s Participating Authority.

A subject matter expert for Halal Framework for Pharmaceuticals in the country since 2009. His contribution is enormous whilst the prime mover of the Malaysian standard of Halal Pharmaceutical guideline. He was an active member of the technical committee for MS 2424:2012 Halal Pharmaceutical Standards – General Guidelines where he instrumented and contributed continuously for Malaysia to be the lead country in the world to drive the Halal Pharmaceutical Standard. He endlessly provides technical guidance to the advancement of MS Halal Pharmaceutical-General Requirements MS 2425:2010 (cosmetics), and the revised MS Halal Pharmaceuticals-General Requirements MS 2424:2019. Both guidelines have served as a pivotal guide for industry players involved in the manufacturing of halal pharmaceutical products and notified cosmetics. In October 2019, he was appointed as permanent member of Steering Committee for Malaysian Halal Certification by Datuk Seri Dr. Mujahid bin Yusof, Minister in the Prime Minister's Department for Religious Affairs.

Charles Lim Meng Yit, a Malaysian aged 67, is our Director. He graduated from University of Science Malaysia as a Pharmacist with a degree of B. Pharm with Honours.

Charles Lim has a career, spanning more than 40 years, in the healthcare, life sciences, biotechnology and biopharmaceutical industry with long experience in sales, marketing & business development in Asia Pacificand techincal expertise in bioseparations from lab to production scale, cGMP bioproduction, downstream bioprocessing & development of biologics and vaccines, turnkey plasma fractionation projectsand GMP facility design. He is a frequent speaker and moderatorat local and International Seminars and Conferences on Biologics in the region and conducted protein and vaccine purification courses at institutes and universities.

He began his career with the Ministry of Health, Malaysia, and after more than a decade as pharmacist and a technical expert in the life science industry in Malaysia he joined Pharmacia Biotech in 1992 to manage their business in South East Asia and became their Vice President, for their separations and downstream processing business in Asia Pacific after the acquisitions by Amersham and GE Healthcare, until 2007. He was also responsible for the cooperation with Pharmadule, Sweden the leading modular turkey facility construction company.

Charles moved to Shanghai China in 2007 where he provided consulting services for business & distributor management, sourcing of funds, technology transfer & acquisition in China and Asia Pacificfor CLIENTS International HK, Atoll GmbH, BIA Separations Austria and Bio-Works Co. Ltd UK. He also teamed up with Emergene GmbH (CEO Dr Joachim Walter) to provide business plan and consultations for turnkey MAB production. He was also expert advisor to Thailand Center of Excellence for Life Sciences (TCELS).

Charles Lim served as a GM of BIA Separations Co. Ltd. China & Asia Pacific, an Austrian based company, from 2010 - 2014 and championed monolith chromatograhy technology for downstream processing of large biomolecules such a viruses and plasmids.

Currently based in Suzhou, Charles Lim is Consultant and Deputy General Manager, International Business of Lisure Science (Suzhou) Co., Ltd the leading Downstream Processing Systems and Solution Provider for the biopharmaceutical industry in China and he has also consulted for other companies such as Charles River Laboratories USA, VirusSure Austria, Suzhou Nanomicro Technology Company, Morimatsu (China) Group and some chinese biologics manufacturers. Charles has a vast network and and knowledge of the biopharmaceutical industry in China.

BOARD

CONTACT US